FMP
Royalty Pharma plc
RPRX
NASDAQ
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
32.49 USD
0.04 (0.123%)
RPRX Financial Statements
Year
2024
2023
2022
2021
Current Assets
1.8B
1.27B
2.55B
2.88B
Cash & Short Term Investments
987.23M
495.31M
2.43B
2.8B
Cash And Cash Equivalents
929.03M
477.01M
1.71B
1.54B
Short Term Investments
58.2M
18.3M
717.04M
1.26B
Net Receivables
26.96M
775.09M
727.92M
682.66M
Inventory
0
0
1
1
Other Current Assets
814.91M
3.8M
90.52M
6.63M
Non-Current Assets
16.42B
15.11B
14.26B
14.64B
Property, Plant & Equipment
0
0
0
0
Goodwill And Intangible Assets
0
1.78M
14.5M
5.67M
Goodwill
0
0
0
0
Intangible Assets
0
1.78M
14.5M
5.67M
Long Term Investments
186.96M
1.01B
14.23B
14.63B
Tax Assets
0
0
0
0
Other Non-Current Assets
16.23B
14.09B
15.13M
4.14M
Other Assets
0
0
0
0
Total Assets
18.22B
16.38B
16.81B
17.52B
-
-
-
-
Current Liabilities
1.25B
161.38M
1.17B
171.25M
Accounts Payable
13.37M
15.16M
7.91M
5.62M
Short Term Debt
997.77M
0
997.51M
0
Tax Payables
0
0
0
0
Deferred Revenue
0
0
0
0
Other Current Liabilities
166.66M
94.53M
107.2M
107.93M
Total Current Liabilities
1.25B
161.38M
1.17B
171.25M
Total Non-Current Liabilities
6.63B
6.14B
6.12B
7.1B
Long-Term Debt
6.61B
6.14B
6.12B
7.1B
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
12.08M
900k
2.5M
0
Total Liabilities
7.88B
6.3B
7.29B
7.27B
Other Liabilities
0
0
0
0
Stockholders Equity
10.34B
6.53B
5.63B
5.78B
Common Stock
45k
45k
107k
106k
Retained Earnings
2.85B
2.52B
1.96B
2.26B
Accumulated Other Comprehensive Income/Loss
0
0
63k
16.49M
Other Shareholders Equity
7.5B
63k
0
0
Total Liabilities and Stockholders Equity
18.22B
16.38B
16.81B
17.52B
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
2.52B
1.96B
2.26B
1.92B
Net Income
859M
1.13B
42.83M
478.75M
Stock Repurchases
-229.65M
-304.76M
0
0
Dividend Paid
-376.46M
-358.33M
-333.32M
-285.18M
Retained Earnings
2.85B
2.52B
1.96B
2.26B
Other Distributions
-278.05M
-110.19M
-623.81M
49.36M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
0
0
0
0
Annual Depreciation
0
395.13M
5.67M
23M
Capital Expenditure
0
0
0
0
Net PPE
0
-395.13M
-5.67M
-23M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
